General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Fixed-income securities information

USD fixed-income securities

Issuer Amount
(in millions)
Coupon Maturity
Novartis Capital Corp. 2,000 2.900% 2015
Novartis Securities Investment Ltd. 3,000 5.125% 2019
Novartis Capital Corp. 1,000 4.400% 2020
Novartis Capital Corp. 1,500 2.400% 2022
Novartis Capital Corp. 2,150 3.400% 2024
Novartis Capital Corp. 500 3.700% 2042
Novartis Capital Corp. 1,850 4.400% 2044

Credit ratings of Novartis AG

Moody's Standard & Poor's Fitch
Short term P-1 A-1+ F1+
Long term Aa3 AA- AA
Outlook Stable Stable Stable

Novartis Capital Corp.

Principal amount USD 2,000,000,000
ISIN US66989HAC25
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 2.900%
Coupon payment date April 24 and October 24, commencing October 24, 2010
Documentation SEC registered shelf registration
First settlement date March 16, 2010
Issue price 99.522
Maturity date April 24, 2015
Joint book-runners Goldman Sachs, JP Morgan, Bank of America Merrill Lynch, Barclays, Citi, Morgan Stanley
Bloomberg NOVNVX 2.9 04/24/15

Novartis Securities Investment Ltd.

Principal amount USD 3,000,000,000
ISIN US66989GAA85
Issuer Novartis Securities Investment Ltd., Bermuda
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 5.125%
Coupon payment date February 10, August 10
Documentation SEC registered shelf registration
First settlement date February 10, 2009
Issue price 99.822
Maturity date February 10, 2019
Joint book-runners JP Morgan, Bank of America, Citi, Goldman Sachs
Bloomberg NOVNVX 5.125 02/10/19

Novartis Capital Corp.

Principal amount USD 1,000,000,000
ISIN US66989HAD08
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 4.400%
Coupon payment date April 24 and October 24, commencing October 24, 2010
Documentation SEC registered shelf registration
First settlement date March 16, 2010
Issue price 99.237
Maturity date April 24, 2020
Joint book-runners Goldman Sachs, JP Morgan, Bank of America Merrill Lynch, Barclays, Citi, Morgan Stanley
Bloomberg NOVNVX 4.4 04/24/20

Novartis Capital Corp.

Principal amount USD 1,500,000,000
ISIN US66989HAE80
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 2.400%
Coupon payment date March 21 and September 21, commencing March 21, 2013
Documentation SEC registered shelf registration
First settlement date September 21, 2012
Issue price 99.225
Maturity date September 21, 2022
Joint book-runners JP Morgan, Morgan Stanley, BNP Paribas, Citi, Bank of America Merrill Lynch, UBS
Bloomberg NOVNVX 2.4 09/21/22

Novartis Capital Corp.

Principal amount USD 2,150,000,000
ISIN US66989HAG39
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 3.400%
Coupon payment date May 6 and November 6, commencing May 6, 2014
Documentation SEC registered shelf registration
First settlement date February 21, 2014
Issue price 99.287
Maturity date May 6, 2024
Joint book-runners Goldman Sachs, Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, JP Morgan
Bloomberg NOVNVX 3.4 05/06/24

Novartis Capital Corp.

Principal amount USD 500,000,000
ISIN US66989HAF55
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 3.700%
Coupon payment date March 21 and September 21, commencing March 21, 2013
Documentation SEC registered shelf registration
First settlement date September 21, 2012
Issue price 98.325
Maturity date September 21, 2042
Joint book-runners JP Morgan, Morgan Stanley, BNP Paribas, Citi, Bank of America Merrill Lynch, UBS
Bloomberg NOVNVX 3.7 09/21/42

Novartis Capital Corp.

Principal amount USD 1,850,000,000
ISIN US66989HAH12
Issuer Novartis Capital Corp., United States
Guarantor Novartis AG, Switzerland
Type Senior unsecured
Coupon 4.400%
Coupon payment date May 6 and November 6, commencing May 6, 2014
Documentation SEC registered shelf registration
First settlement date February 21, 2014
Issue price 99.196
Maturity date May 6, 2044
Joint book-runners Goldman Sachs, Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, JP Morgan
Bloomberg NOVNVX 4.4 05/06/44


The information provided on this website does not constitute investment advice, or an offer of, or an invitation by, or on behalf of, Novartis AG or any of its subsidiaries, to subscribe for, purchase or sell any securities, including any of the securities described above and below. The information provided also does not constitute an offer, and may not be used for the purpose of an offer to, or a solicitation by, anyone in any jurisdiction or in any circumstances in which such an offer or solicitation is not authorized or is unlawful. You should always seek advice whether governing law permits the use or possession of the information provided.

Neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any direct or consequential loss arising from any use of the information provided. In particular, neither Novartis AG, nor any of its subsidiaries or employees accepts any liability for any third party content that may be viewed on this site. All information provided is also qualified in its entirety by reference to the relevant prospectuses, supplemental information or other documentation related to the securities described above and below.

Stock chart
Q3 Results 2013

On Thursday, April 24, Novartis will announce its results for the first quarter of 2014